![Eva Ehrnrooth](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profil
Eva Ehrnrooth worked as a Medical Director in Oncology at Novo Nordisk A from 2006 to 2008, and at Genmab A from 2008 to 2010.
She is currently the Chief Medical Officer at IO Biotech, Inc. since 2017.
Dr. Ehrnrooth holds a doctorate degree from the University of Aarhus.
Tidigare kända positioner av Eva Ehrnrooth
| Företag | Position | Slut |
|---|---|---|
| IO BIOTECH, INC. | Teknisk/Vetenskaplig/F&U Direktör | 2023-07-18 |
| GENMAB A/S | Teknisk/Vetenskaplig/F&U Direktör | 2010-02-01 |
| NOVO NORDISK A/S | Företagsledare/Principal | 2008-05-01 |
Eva Ehrnrooths utbildningar
Erfarenheter
Innehade positioner
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Relationer
30
Första gradens relationer
4
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
Kopplade företag
| Privata företag | 4 |
|---|---|
Novo Nordisk A/S
 Novo Nordisk A/S Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products for diabetes care | Health Technology |
Genmab A/S
 Genmab A/S BiotechnologyHealth Technology Operates as a biotechnology company for improving the lives of people with cancer and serious diseases through antibody medicines | Health Technology |
University of Aarhus
 University of Aarhus Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
IO Biotech, Inc.
 IO Biotech, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that develops novel, immune-modulating cancer therapies | Health Technology |
